Hepatocyte stability tests play a critical role in the early stages of drug discovery and development. These tests help researchers evaluate the metabolism and safety
Recently, Pfizer of the United States and its German partner BioNTech countersued rival Moderna for the patent of the COVID-19 vaccine technology. broad” and “unenforceable”.
On November 30, 2022, Ferring Pharmaceuticals announced that its microbiome therapy REBYOTA® (RBX2660) was approved by the FDA, becoming the first approved fecal microbial therapy.
On November 10, when AstraZeneca announced its third-quarter 2022 results, it also announced that it would not submit a listing application for the new crown
The excellent efficacy of targeted drugs and the inevitable problem of drug resistance have been in a state of ebb and flow. Researchers continue to
On November 7, GSK announced that the Phase III open-label, randomized, head-to-head superiority DREAMM-3 trial failed to meet the primary endpoint of progression-free survival (PFS).
On November 3, Affimed announced that it will present an update on the ongoing Phase I/II clinical trial at the ASH Congress. The study was
AB-836, a next-generation oral hepatitis B virus (HBV) capsid inhibitor (class II capsid inhibitor) that Arbutus Biopharma is developing for the treatment of chronic hepatitis
In July of this year, DeepMind, which developed AlphaFold, announced that it had increased the amount of predicted protein structure data from 1 million to
On November 4, German Chancellor Schultz announced a new agreement with the Chinese government. The Chinese government approved Germany’s BioNTech’s covid-19 vaccine for use by
On November 3, the Institute of Clinical and Economic Review (ICER) announced that, after a cost-benefit analysis, it assessed the price ceiling of Roctavian (valoctocogene
Ascendis Pharma announced that the FDA has accepted and granted Priority Review status for TransCon PTH for the treatment of adult patients with hypoparathyroidism, with
